Drug data last refreshed Yesterday
PIPRACIL (piperacillin sodium) is a broad-spectrum injectable penicillin antibiotic approved in 1981 for treating intra-abdominal infections. It works by inhibiting bacterial cell wall biosynthesis, exerting bactericidal activity against susceptible pathogens during active multiplication. The drug is administered by injection and remains a foundational antibiotic for serious abdominal cavity infections.
As LOE approaches, the brand team will shift focus toward lifecycle extension, cost optimization, and managed transition strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PIPRACIL offers limited career growth in innovation but provides solid experience in mature product management, managed care negotiations, and cost optimization in a highly competitive generic market. This role is ideal for professionals seeking operational expertise and stability rather than launches or blockbuster growth.
Worked on PIPRACIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo